SavedAdd your journal

Journals / Experimental Biomedical Research / 2020 / Cilt: 3 - Sayı: 1

Role of N-terminal pro b-type natriuretic peptide (NT-pro-BNP) in compensated chronic kidney disease

Tuba T. DUMAN
Hikmet TEKÇE
Buket Kin TEKÇE
Pages
30–36
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the light of all these data, it is possible to suggest that NT-pro BNP is associated with hypervolemia and therefore increased cardiovascular mortality in subjects with CKD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate the role of N-terminal pro b-type natriuretic peptide (NT-pro-BNP) in the evaluation of hypervolemia in chronic kidney disease (CKD) and its relationship with CKD.
📊
Key Findings & Data:Results: NT-pro BNP levels were correlated with urea (r = 0.66, p <0.01), creatinine (r = 0.69, p <0.01) and phosphorus (r = 0.36, p <0.01) values and were negative correlated with hemoglobin (r = -0.32, p = 0.01), hematocrit (r = -0.36, p <0.01), albumin (r = -0.29, p = 0.02) and glomerular filtration rate (GFR) values (r = -0.35, p <0.01).
💡
Conclusion & Impact:In the light of all these data, it is possible to suggest that NT-pro BNP is associated with hypervolemia and therefore increased cardiovascular mortality in subjects with CKD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aim: To evaluate the role of N-terminal pro b-type natriuretic peptide (NT-pro-BNP) in the evaluation of hypervolemia in chronic kidney disease (CKD) and its relationship with CKD. Methods: Sixty compensated chronic kidney disease patients enrolled in this study. NT-pro BNP levels and other routine biochemical laboratory parameters are studied. The associations between results were analyzed. Results: NT-pro BNP levels were correlated with urea (r = 0.66, p <0.01), creatinine (r = 0.69, p <0.01) and phosphorus (r = 0.36, p <0.01) values and were negative correlated with hemoglobin (r = -0.32, p = 0.01), hematocrit (r = -0.36, p <0.01), albumin (r = -0.29, p = 0.02) and glomerular filtration rate (GFR) values (r = -0.35, p <0.01). Conclusion: The positive correlation between NT-pro BNP levels and urea and creatinine values in our study and the negative correlation with GFR support that the severity of hypervolemia increases as the CKD stage progresses. BNP and NT-pro BNP are strong predictors of all-cause cardiovascular mortality in asymptomatic CKD patients. In the light of all these data, it is possible to suggest that NT-pro BNP is associated with hypervolemia and therefore increased cardiovascular mortality in subjects with CKD.

🔖

Cite This Article

DUMAN, T. T., TEKÇE, H., TEKÇE, B. K. (2020). Role of N-terminal pro b-type natriuretic peptide (NT-pro-BNP) in compensated chronic kidney disease. Experimental Biomedical Research, Cilt: 3 - Sayı: 1, 30–36. https://ajindex.com/articles/160980

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003
  2. 42(5): 1050–65. [2]Amann K, Rychlík I, Miltenberger-Milteny G, et al. Left ventricular hypertrophy in renal failure. Kidney Int Suppl.1998
  3. Krane V, Heinrich F, Meesmann M, et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol. 2009
  4. 4(2): 394-400. [4]Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-Bnatriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007
  5. 50(6): 1009–19. [5]Madsen LH, Ladefoged S, Corell P, et al. Nterminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007
  6. 71(6): 548–54. [6]Wang AY, Lam CW, Wang M, et al. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant. 2009
  7. 24(6):1962– 69. [7]Wang AY, Lam CW, Yu CM, et al. Nterminal probrain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol. 2007
  8. 321 –30. [8]Wang AY. Clinical utility of natriuretic peptides in dialysis patients. Semin Dial. 2012
  9. 25(3):326–333. [9]Baughman KL. B-type natriuretic peptide -- a window to the heart. N Engl J Med. 2002
  10. 347(3):158–59. [10] de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet. 2003
  11. 362 (9380): 316–22. [11] Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976
  12. 16(1):31 –41. [12] Süleymanlar G, Utaş C, Arinsoy T, et al. A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study. Nephrol Dial Transplant. 2011
  13. 26(6):1862– 71. [13] Ausma J, Litjens N, Lenders MH, et al. Time course of atrial fibrillation-induced cellular structural remodeling in atria of the goat. J Mol Cell Cardiol. 2001
  14. 33(12): 2083–94. [14] Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stag